Bray R A, Nolen J D L, Larsen C, Pearson T, Newell K A, Kokko K, Guasch A, Tso P, Mendel J B, Gebel H M
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA.
Am J Transplant. 2006 Oct;6(10):2307-15. doi: 10.1111/j.1600-6143.2006.01521.x. Epub 2006 Aug 25.
Renal transplant patients sensitized to HLA antigens comprise nearly one-third of the UNOS wait-list and receive 14% of deceased donor (DD) transplants, a rate half that of unsensitized patients. Between 1999 and 2003, we performed 492 adult renal transplants from DD; 120 patients (approximately 25%) had a panel reactive antibody (PRA) of >30%, with nearly half (n = 58) having a PRA of >80%. Our approach is based upon high-resolution solid-phase HLA antibody analysis to identify class I/II antibodies and a 'virtual crossmatch' to predict compatible donor/recipient combinations. Recipients are excluded from the United Network for Organ Sharing match run if donors possess unacceptable antigens. Thus, when sensitized patients appear on the match run, they have a high probability of a negative final crossmatch. Here, we describe our 5-year experience with this approach. Five-year graft survival ranged from 66% to 70% among unsensitized (n = 272), moderately sensitized (PRA < 30%, n = 100) and highly sensitized (>30% PRA; n = 120) patients, equal to the average national graft survival (65.7%). The application of this approach (the Emory Algorithm) provides a logical and systematic approach to improve the access of sensitized patients to DD organs and promote more equitable allocation to a highly disadvantaged group of patients awaiting renal transplantation.
对人类白细胞抗原(HLA)抗原致敏的肾移植受者占器官共享联合网络(UNOS)等待名单的近三分之一,接受了14%的 deceased donor(DD)肾移植,这一比例仅为未致敏患者的一半。1999年至2003年期间,我们对492例成年患者进行了DD肾移植;120例患者(约25%)的群体反应性抗体(PRA)>30%,其中近一半(n = 58)的PRA>80%。我们的方法基于高分辨率固相HLA抗体分析以识别I/II类抗体,并通过“虚拟交叉配型”来预测相容的供体/受体组合。如果供体具有不可接受的抗原,则将受者排除在器官共享联合网络的配型流程之外。因此,当致敏患者出现在配型流程中时,他们最终交叉配型阴性的可能性很高。在此,我们描述我们采用这种方法的5年经验。未致敏患者(n = 272)、中度致敏患者(PRA<30%,n = 100)和高度致敏患者(PRA>30%;n = 120)的5年移植物存活率在66%至70%之间,与全国平均移植物存活率(65.7%)相当。这种方法(埃默里算法)的应用提供了一种合理且系统的方法,可改善致敏患者获得DD器官的机会,并促进更公平地分配给等待肾移植的高度弱势群体。